 In this issue , Alric and colleagues demonstrate through real-world experience that grazoprevir-elbasvir is safe and effective for treating hepatitis<pathogen><disease><symptom> C<pathogen><disease> in advanced kidney disease<disease> patients with higher comorbidity burdens. This commentary highlights that this and similar studies have primarily focused on treatment safety and efficacy , rather than the clinical impact of viral eradication. Critical knowledge gaps including which patients to treat , and when , as well as potential management strategies that may improve outcomes , are discussed.